Title: Case Report: Febrile Neutropenia in a Patient with Carcinoma of Larynx
Authors: B. Sunil Kumar Nayak, G. Divya Sri, K.Abhinay, Dr K. Srinath, Dr M.G Irfan Ahmed Khan
DOI: https://dx.doi.org/10.18535/jmscr/v6i11.58
Abstract
Febrile neutropenia and myelosupression is one of the serious adverse effect or the toxic effect of most anti-cancer drugs. When these drugs are prescribed, myelosupression is seen by which pancytopenia (where all blood cells are decreased) is seen. Granulocyte colony stimulating factors are given in order to regain the cell counts. In this case report we discuss about the patient who has diagnosed with carcinoma of larynx experienced the pancytopenia and how he was managed.
Background: Febrile neutropenia is one of the most serious complications of the cancer chemotherapy drugs. Febrile neutropenia is a life threatening condition where the neutrophil count gets lowered which leads to enhance some of the factors associated with morbidity, mortality and financial costs of the patients which are associated with supportive care. The colony stimulating factor is helpful in preventing the adverse effects of anti-cancer drugs such as neutropenia who receives the chemotherapy both in curative patients and palliative care patients.
Keywords: Febrile neutropenia, colony stimulating factors, filgrastim, myelosupression, meropenum.